|
DSMB 7th review??
|
4
|
Resverlogix Corp.
|
Jul 17, 2018 03:41PM
|
|
Re: Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
|
4
|
Resverlogix Corp.
|
Jan 12, 2021 02:36PM
|
|
Re: 2 year extension
|
4
|
Resverlogix Corp.
|
May 14, 2024 11:25AM
|
|
Re: A Fictitious Conversation at a Fictitious Company
|
4
|
Resverlogix Corp.
|
Sep 08, 2016 02:22PM
|
|
Re: Potential Scope of Indications for Apabetalone (selective BRD/BD inhibition)
|
4
|
Resverlogix Corp.
|
Nov 14, 2022 06:12PM
|
|
Re: find it interesting that RVXCF.....
|
4
|
Resverlogix Corp.
|
Nov 10, 2022 11:26AM
|
|
Zenith Private placement??
|
4
|
Zenith Epigenetics
|
Feb 20, 2018 10:15AM
|
|
Re: Spreading the gospel....
|
4
|
Resverlogix Corp.
|
Dec 10, 2017 10:55AM
|
|
Re: IR
|
4
|
Resverlogix Corp.
|
Jan 13, 2023 02:13PM
|
|
Another Epigenetics co get bought out, not many left
|
4
|
Zenith Epigenetics
|
Jul 10, 2022 08:38AM
|
|
Re: IR
|
4
|
Resverlogix Corp.
|
Jan 18, 2023 02:33PM
|
|
Re: Top Shareholders of RVX
|
4
|
Resverlogix Corp.
|
Mar 01, 2020 08:18AM
|
|
Re: Top marks fouremm
|
4
|
Resverlogix Corp.
|
Dec 11, 2015 08:17AM
|
|
Re: Breakthrough Therapy Designation Application
|
4
|
Resverlogix Corp.
|
Dec 06, 2019 10:22AM
|
|
Re: BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
|
4
|
Resverlogix Corp.
|
Dec 05, 2017 01:20PM
|
|
Re: Trial
|
4
|
Zenith Epigenetics
|
Nov 21, 2019 01:09PM
|
|
New approach to Alzheimers Disease Beyond Amyloid Plagues
|
4
|
Resverlogix Corp.
|
Dec 17, 2019 11:15AM
|
|
Re: ZEN-3694 mCRPC Trial Status
|
4
|
Zenith Epigenetics
|
Oct 25, 2017 04:36PM
|
|
Re: Additional Exempt Distribution- 2023-03-31
|
4
|
Zenith Epigenetics
|
Apr 15, 2023 03:53PM
|
|
Re: The waiting game.....
|
4
|
Resverlogix Corp.
|
Feb 12, 2019 02:58PM
|
